TY - STD TI - Halimi V, Daci A, Stojanovska S, Panovska-Stavridis I, Stevanovic M, Filipce V, et al. Current regulatory approaches for accessing potential COVID-19 therapies. J Pharm Policy Pract. 2020. ID - ref1 ER - TY - STD TI - Food and Drug Administration (FDA). Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate. [Internet]. [cited 2020 July 19]. Available from: https://www.fda.gov/media/138945/download. UR - https://www.fda.gov/media/138945/download ID - ref2 ER - TY - STD TI - Recovery statement. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir [Internet]. [cited 2020 July 19]. Available from: www.recoverytrial.net. UR - http://www.recoverytrial.net ID - ref3 ER - TY - STD TI - Food and Drug Administration (FDA). FDA COMBATING COVID-19 WITH THERAPEUTICS. [Internet]. [cited 2020 July 19]. Available from: https://www.fda.gov/media/136832/download. UR - https://www.fda.gov/media/136832/download ID - ref4 ER - TY - STD TI - Food and Drug Administration (FDA). Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease [Internet]. [cited 2020 July 19]. Available from: https://www.fda.gov/media/136534/download. UR - https://www.fda.gov/media/136534/download ID - ref5 ER - TY - STD TI - Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020. ID - ref6 ER - TY - STD TI - Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020. ID - ref7 ER - TY - STD TI - Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020. ID - ref8 ER - TY - STD TI - Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020. ID - ref9 ER - TY - STD TI - Liu T, Zhang J, Yang Y, Zhang L, Ma H, Li Z, et al. The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019. SSRN Electron J. 2019:2020. ID - ref10 ER - TY - STD TI - Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020. ID - ref11 ER - TY - BOOK AU - Toniati, P. AU - Piva, S. AU - Cattalini, M. AU - Garrafa, E. AU - Regola, F. AU - Castelli, F. PY - 2020 DA - 2020// TI - Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia PB - Italy. Autoimmun CY - Rev ID - Toniati2020 ER - TY - STD TI - Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020. ID - ref13 ER - TY - STD TI - Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020. ID - ref14 ER - TY - STD TI - Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020. ID - ref15 ER - TY - STD TI - European Medicines Agency (EMA). Annex I Conditions of use, conditions for distribution and patients targeted adressed to Member States Remdesivir Gilead. [Internet]. [cited 2020 Jul 19] Available online:https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring-adressed_en-2.pdf. UR - https://www.ema.europa.eu/en/documents/other/conditions-use-conditions-distribution-patients-targeted-conditions-safety-monitoring-adressed_en-2.pdf ID - ref16 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). MHRA issues a scientific opinion for the first medicine to treat COVID-19 in the UK - GOV.UK [Internet]. [cited 2020 Jul 1]. Available from: https://www.gov.uk/government/news/mhra-supports-the-use-of-remdesivir-as-the-first-medicine-to-treat-covid-19-in-the-uk. UR - https://www.gov.uk/government/news/mhra-supports-the-use-of-remdesivir-as-the-first-medicine-to-treat-covid-19-in-the-uk ID - ref17 ER - TY - STD TI - Agenzia Italiana del Farmaco (AIFA). Programmi di uso compassionevole – COVID-19 | Agenzia Italiana del Farmaco [Internet]. [cited 2020 Jul 12]. Available from: https://www.aifa.gov.it/programmi-di-uso-compassionevole-covid-19. UR - https://www.aifa.gov.it/programmi-di-uso-compassionevole-covid-19 ID - ref18 ER - TY - STD TI - ClinicalTrials.gov National Library of Medicine (US).Identifier NCT04323761. Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Jul 19]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04323761?term=remdesivir&type=Expn&cond=Covid-19&draw=2&rank=1. UR - https://www.clinicaltrials.gov/ct2/show/NCT04323761?term=remdesivir&type=Expn&cond=Covid-19&draw=2&rank=1 ID - ref19 ER - TY - STD TI - ClinicalTrials.gov National Library of Medicine (US).Identifier NCT04302766. Expanded Access Remdesivir (RDV; GS-5734TM) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Jul 19]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04302766. UR - https://www.clinicaltrials.gov/ct2/show/NCT04302766 ID - ref20 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency(MHRA). EAMS Information for HCP [Remdesivir 100 mg concentrate for solution for infusion] EAMS 11972/0002 Remdesivir 100 mg concentrate for solution for infusion Early Access to Medicines Scheme-Treatment protocol-Information for healthcare professionals. [Internet]. [cited 2020 Jul 1] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887275/EAMS__11972_0002__TP__HCP_Solution.pdf. UR - https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887275/EAMS__11972_0002__TP__HCP_Solution.pdf ID - ref21 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). EAMS Information for HCP [Remdesivir 100 mg powder for concentrate for solution for infusion]. [Internet]. [cited 2020 Jul 1] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887276/EAMS_11972_0001__TP_HCP_Powder.pdf. UR - https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887276/EAMS_11972_0001__TP_HCP_Powder.pdf ID - ref22 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). EAMS Information for Patients [Remdesivir 100 mg powder for concentrate for solution for infusion] . [Internet]. [cited 2020 Jul 1] Available from: https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-remdesivir-in-the-treatment-of-patients-hospitalised-with-suspected-or-laboratory-confirme/treatment-protocol-for-patients_eams-119720001-remdesivir-100-mg-powder-for-concentrate-for-solution-for-infusion. UR - https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-remdesivir-in-the-treatment-of-patients-hospitalised-with-suspected-or-laboratory-confirme/treatment-protocol-for-patients_eams-119720001-remdesivir-100-mg-powder-for-concentrate-for-solution-for-infusion ID - ref23 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). EAMS information for patients [remdesivir 100 mg concentrate for solution for infusion] [Internet]. [cited 2020 Jul 1] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887278/EAMS_TP_for_Patients_11972_0002_Solution.pdf. UR - https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887278/EAMS_TP_for_Patients_11972_0002_Solution.pdf ID - ref24 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). EAMS pharmacovigilance system [remdesivir 100 mg powder for concentrate for solution for infusion and remdesivir 100 mg concentrate for solution for infusion] EAMS 11972/0001 Remdesivir 100 mg powder for concentrate for solution for infusion EAMS 11972/0002 Remdesivir 100 mg concentrate for solution for infusion early access to medicines scheme-treatment protocol-information on the pharmacovigilance system and requirements for reporting safety data [Internet]. [cited 2020 Jul 1] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887279/EAMS_TP_on_PVS_11972_0001_and_11972_0002.pdf;. UR - https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887279/EAMS_TP_on_PVS_11972_0001_and_11972_0002.pdf; ID - ref25 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). Early access to medicines scientific opinion-public assessment report product remdesivir 100 mg powder for concentrate for solution for infusion remdesivir 100 mg concentrate for solution for infusion [Internet]. [cited 2020 Jul 1]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897613/PAR_EAMS_11972_0001_AND_11972_0002__PAR.pdf. UR - https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/897613/PAR_EAMS_11972_0001_AND_11972_0002__PAR.pdf ID - ref26 ER - TY - STD TI - European Medicines Agency (EMA). Summary on compassionate use for Remdesivir Gilead [Internet]. [cited 2020 Apr 12]. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf. UR - https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf ID - ref27 ER - TY - STD TI - Food and Drug Administration (FDA). Fact sheet for health care providers emergency use authorisation (EUA) of remdesivir (GS-5734TM) ). [Internet]. [cited 2020 Jul 4]. Available from: https://www.fda.gov/media/137566/download. UR - https://www.fda.gov/media/137566/download ID - ref28 ER - TY - STD TI - Food and Drug Administration (FDA). Fact sheet for patients and parent/caregivers emergency use authorization (EUA) of remdesivir for coronavirus disease 2019 [Internet]. [cited 2020 Jul 4]. Available from: https://www.fda.gov/media/137565/download. UR - https://www.fda.gov/media/137565/download ID - ref29 ER - TY - STD TI - Food and Drug Administration (FDA). Frequently asked questions on the emergency use authorization for remdesivir for certain hospitalized COVID-19 patients. [Internet]. [cited 2020 Jul 4]. Available from:https://www.fda.gov/media/137574/download. UR - https://www.fda.gov/media/137574/download ID - ref30 ER - TY - STD TI - Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020. ID - ref31 ER - TY - STD TI - Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020. ID - ref32 ER - TY - STD TI - Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Jun 5];NEJMoa2015301. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2015301. UR - http://www.nejm.org/doi/10.1056/NEJMoa2015301 ID - ref33 ER - TY - STD TI - Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Jun 5];NEJMoa2007764. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2007764. UR - http://www.nejm.org/doi/10.1056/NEJMoa2007764 ID - ref34 ER - TY - STD TI - Gilead Sciences. Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials [Internet]. [cited 2020 Jun 2]. Available from: https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials. UR - https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials ID - ref35 ER - TY - STD TI - European Medicines Agency (EMA). EMA provides recommendations on compassionate use of remdesivir for COVID-19 | European Medicines Agency [Internet]. [cited 2020 Jun 4]. Available from: https://www.ema.europa.eu/en/news/ema-provides-recommendations-compassionate-use-remdesivir-covid-19. UR - https://www.ema.europa.eu/en/news/ema-provides-recommendations-compassionate-use-remdesivir-covid-19 ID - ref36 ER - TY - STD TI - European Medicines Agency. Treatments and vaccines for COVID-19 | European Medicines Agency [Internet]. [cited 2020 Apr 21]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19. UR - https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19 ID - ref37 ER - TY - STD TI - Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020. ID - ref38 ER - TY - STD TI - European Union; European Medicines Agency. Guideline on compassionate use of medicinal products, pursuant to Article 83 of Regulation (EC) No 726/2004. 2007; Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-726/2004_en.pdf;. UR - https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-compassionate-use-medicinal-products-pursuant-article-83-regulation-ec-no-726/2004_en.pdf; ID - ref39 ER - TY - STD TI - Food and Drug Administration. Expanded access to investigational drugs for treatment use — questions and answers [Internet]. 2017. p. 1473–4. Available from: https://www.fda.gov/media/85675/download;. UR - https://www.fda.gov/media/85675/download; ID - ref40 ER - TY - STD TI - European Parliament and the Council of the European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [Internet]. Off. J. L 311 , 28/11/2001 P. 0067 - 0128; OPOCE; [cited 2020 Jun 9]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32001L0083&from=EN. UR - https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32001L0083&from=EN ID - ref41 ER - TY - STD TI - European Medicines Agency (EMA). EMA starts rolling review of remdesivir for COVID-19 | European Medicines Agency [Internet]. [cited 2020 Jun 12]. Available from: https://www.ema.europa.eu/en/news/ema-starts-rolling-review-remdesivir-covid-19. UR - https://www.ema.europa.eu/en/news/ema-starts-rolling-review-remdesivir-covid-19 ID - ref42 ER - TY - STD TI - European Medicines Agency (EMA). European Public Assessment Report (EPAR) of Venklury (remdesivir) [Internet]. [cited 2020 Jun 9].Available from: www.ema.europa.eu/contact;. UR - http://www.ema.europa.eu/contact; ID - ref43 ER - TY - STD TI - European Medicines Agency (EMA). First COVID-19 treatment recommended for EU authorisation | European Medicines Agency [Internet]. [cited 2020 Jul 19]. Available from: https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation. UR - https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation ID - ref44 ER - TY - STD TI - Medicines and Healthcare products Regulatory Agency (MHRA). [Withdrawn] Early access to medicines scheme (EAMS) scientific opinion: remdesivir in the treatment of patients hospitalised with suspected or laboratory-confirmed SARS-CoV-2 infection who meet the clinical criteria - GOV.UK [Internet]. [cited 2020 Jul 19]. Available from: https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-remdesivir-in-the-treatment-of-patients-hospitalised-with-suspected-or-laboratory-confirme;. UR - https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-scientific-opinion-remdesivir-in-the-treatment-of-patients-hospitalised-with-suspected-or-laboratory-confirme; ID - ref45 ER - TY - STD TI - The Therapeutic Goods Administration (TGA). Australia’s first COVID treatment approved | Therapeutic Goods Administration (TGA) [Internet]. [cited 2020 Jul 19]. Available from: https://www.tga.gov.au/media-release/australias-first-covid-treatment-approved. UR - https://www.tga.gov.au/media-release/australias-first-covid-treatment-approved ID - ref46 ER - TY - STD TI - Gilead Sciences. An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences [Internet]. [cited 2020 Jul 19]. Available from: https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-29. UR - https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-29 ID - ref47 ER - TY - STD TI - Gilead Sciences. An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences [Internet]. [cited 2020 Jul 19]. Available from: https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-22. UR - https://stories.gilead.com/articles/an-open-letter-from-daniel-oday-june-22 ID - ref48 ER - TY - STD TI - U.S. National Library of Medicine Clinicaltrials.gov. A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe covid-19 pneumonia - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Jul 19]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04409262?term=remdesivir&draw=3&rank=11. UR - https://www.clinicaltrials.gov/ct2/show/NCT04409262?term=remdesivir&draw=3&rank=11 ID - ref49 ER - TY - STD TI - U.S. National Library of Medicine ClinicalTrials.gov. Adaptive COVID-19 Treatment Trial 2 (ACTT-2) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 Jul 19]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04401579?term=remdesivir&draw=2&rank=13. UR - https://www.clinicaltrials.gov/ct2/show/NCT04401579?term=remdesivir&draw=2&rank=13 ID - ref50 ER - TY - STD TI - U.S. National Library of Medicine ClinicalTrials.gov. Study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734TM) in participants from birth to < 18 years of age with coronavirus disease 2019 (COVID-19) - full text view - ClinicalTrials.gov [Internet]. [cited 2020 Jul 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT04431453. UR - https://clinicaltrials.gov/ct2/show/NCT04431453 ID - ref51 ER - TY - STD TI - Gilead Sciences. Gilead presents additional data on investigational antiviral remdesivir for the treatment of COVID-19 [Internet]. [cited 2020 Jul 19]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19. UR - https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19 ID - ref52 ER -